September 1, 2021
In Vitro Potency Assays for Assessing the Function of anti-PD-1 Checkpoint Inhibitors
In this post we explore the different in vitro potency assays for assessing the function of anti-PD-1 checkpoint inhibitors, which are used to test the T cell response of anti-PD-1 (programmed death-1) agents.
LEARN MORE
August 2, 2021
In vivo preclinical models for immune-mediated inflammatory disease drug development
In this blog we will explore immune-mediated inflammatory diseases (IMIDs)—which represent a diverse group of ...
LEARN MORE
July 5, 2021
Preclinical Models for Bispecific T Cell Engager Development
Last month we hosted a webinar with Dr. Ludovic Bourré, Senior Director of Scientific Engagement at CrownBio, focused ...
LEARN MORE
December 18, 2020
Factors to Consider When Selecting a Next Generation Sequencing (NGS) Technology
Explore the main factors you need to consider before choosing and using next generation sequencing (NGS).
LEARN MORE
October 28, 2019
Biomarker Discovery and MOA Evaluation through Genomic and Proteomic Profiling at AACR-NCI-EORTC 2019
This week in Boston we’re presenting data on our new analysis platform and preclinical technologies. This post recaps ...
LEARN MORE
October 25, 2019
How to Detect, Characterize, and Evaluate CAR-Ts: Top 13 Questions
Review key questions on preclinical models and rare cell analysis technology for assessing CAR-T cell therapies from ...
LEARN MORE
May 7, 2019
Combination Therapies and Tumor Homograft Models
Learn more about using tumor homograft models to assess oncology combination regimens, including immunotherapies.
LEARN MORE
April 25, 2019
Large-Scale Immunotherapy Screening: How and Why?
Learn more about the need for large-scale cancer immunotherapy screens and the different immunocompetent models ...
LEARN MORE
February 6, 2019
Target Engagement Studies with Syngeneic Tumor Models
Syngeneic tumor models are a rapid and high-throughput option for novel drug discovery. Here’s how to use them for ...
LEARN MORE
January 29, 2019
Using Syngeneic Tumor Models for POC Studies
Syngeneic tumor models are a predictive, high-throughput option for validating novel therapeutic approaches. Here’s how ...
LEARN MORE
